The focus of this two days training will be on providing an update of ongoing activities regarding medicines’ risk and signal management. The first day will be an opportunity to provide the participants practical advice on RMP drafting and preparation as well the accessors point of view in evaluating an RMP. Moreover, the increasing number of biosimilars and biologicals being authorized highlighted a need to better streamline the safety specification for these products so that only risks that are important for risk management and relevant for the benefit-risk of the product are included in the RMP. Also, a dedicated section on the risk management aspects of the new GVP guidance on special populations such as children and elderly will be provided.
On the second day participants will have the opportunity to get an insight on the current signal detection and management guidelines and tools, as also on the EMA pilot phase using Eudravigilance Data Analysis System (EVDAS). Regarding signal management using EVDAS, a pilot phase including a limited number of active substances selected based on the list of medicinal products subject to additional monitoring is currently ongoing. During the signal management session, pragmatic approaches, lessons learned, as also processes for signal management and eRMR assessment will be discussed. Finally, during this training, an outlook of current and future challenges in pharmacovigilance focusing on the impact of the coming into force of the General Data Protection (GDPR) Regulation in May 2018 will be given and discussed.
Virtual Event/ Online Event